安捷伦海马XF Pro分析仪< / >,以新的pharma-oriented工作流解决方案整合先进的实验设计和分析工具。增强性能、更健壮和高效的工作流程,优化用户体验,XF Pro支持运营商访问在任何技能水平最先进的细胞代谢分析技术对理解细胞的命运,健身,和功能。< br > < / p > < p > < / p > < p >临床治疗发现工作流对细胞分析要求高,与免疫学和疾病研究人员越来越多地使用罕见,体外,转基因细胞构建更好的疾病模型。解决实时监控活细胞的兴趣越来越浓,新的XF Pro分析仪包含一套硬件和软件增强,提高测量性能和数据解释。这些增强功能,就能很容易地识别新药物靶点,验证目标对细胞功能的影响,优化疾病模型,并确定药物安全性和抗肿瘤T细胞疗法的潜力。< br > < / p > < p > < / p > < p > "专用工作流解决方案XF Pro提供了增强的性能和用户体验,尤其是在制药和生物制药治疗的发展,和毒性项目,”理查德•费尔南德斯说助理副总裁和总经理安捷伦的细胞分析,海马,Luxcel,微型板块业务。“这突显了安捷伦的承诺向发展中故意端到端着重于解决方案的创新,继续带头应用分析和研究应用,包括直接代谢分析。”

"The launch of the XF Pro is very much a customer-driven event. Through collaboration and intentional conversations with our customers and key opinion leaders, we recognized the need for a live-cell metabolic analysis platform which makes sophisticated analysis even more accessible for both experienced users as well as novices,” added Chris Braun, associate vice president of Marketing for Agilent’s Cell Analysis Division. “Primarily targeting the pharma/biopharma sector, but beneficial to all our customers, the XF Pro incorporates critical metabolic insights into researchers’ discovery workflows to facilitate even higher quality data where it matters most.”

The XF Pro Analyzer is expected to enhance critical aspects of live-cell analysis, particularly for researchers working in immunotherapy, early drug discovery, and preclinical safety assessment. By delivering better precision at a low oxygen consumption rate (OCR), the XF Pro Analyzer allows analysts to confidently interrogate more immune cell types, as well as cell types that are bioenergetically compromised. The instrument also features pharma-tailored workflows for harnessing robust cellular metabolism measurements while handling suspension cell types, along with simplified automation enablement and analytical instrument qualification (AIQ). 

">